The first two adults with recessive dystrophic epidermolysis bullosa (RDEB) treated with the topical gene therapy candidate KB103 experienced increased…
Articles by Patricia Inácio, PhD
A family of enzymes with genome-editing function to enhance immune system responses are driving the high rate of skin cancer…
FCX-007, an experimental gene therapy developed by Fibrocell Science in collaboration with Precigen (a subsidiary of Intrexon), continues…
Collagen type VII-filled vesicles released by bone marrow-derived mesenchymal stem cells may explain the therapeutic benefits of these cells in…
Using a simple blood sample may be sufficient to detect a biomarker for skin cancer in epidermolysis bullosa patients, a new…
Scientists have found that using inhibitors on specific parts of the so-called complement system, part of the immune system that…
Injecting fibroblasts directly into a wound led to higher rates of healing and complete closure than other more common methods…
Abeona Therapeutics‘ EB-101, a gene therapy in development for patients with recessive dystrophic epidermolysis bullosa (RDEB), has received the …
Feeding through a tube inserted directly into the stomach, a process known as gastrostomy, is a potentially beneficial strategy for…
A lack of vitamin D is a potential key factor in epidermolysis bullosa acquisita (EBA), researchers have found. Using mouse…
Krystal Biotech recently announced that its leading investigational therapy for epidermolysis bullosa, KB103, has received clearance from the Recombinant DNA Advisory…
Short-term application of the antibiotic gentamicin, either topical or intradermal, reversed the effect of nonsense mutations in a small group…